NUC-1031 in biliary tract cancer: from bench to bedside and back?
Cancer Chemother Pharmacol
; 85(6): 1011-1014, 2020 06.
Article
em En
| MEDLINE
| ID: mdl-32476108
ABSTRACT
In preclinical models of biliary tract cancer, NUC-1031 showed less potency than gemcitabine, no correlation with potential biomarkers and only moderate additive interaction in combination with cisplatin. These findings should prompt further careful pharmacological and translational studies to better define the purported therapeutic advantage of NUC-1031 over gemcitabine. That would be a more cautious approach than the phase III clinical trial which is planning to enrol 828 patients with biliary tract tumours to compare gemcitabine/cisplatin "conventional" treatment with or without NUC-1031.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias do Sistema Biliar
/
Monofosfato de Citidina
/
Pesquisa Translacional Biomédica
/
Antineoplásicos
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article